Precision BioSciences (NASDAQ:DTIL) Director Geno Germano Purchases 3,000 Shares of Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) Director Geno Germano purchased 3,000 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The shares were bought at an average price of $4.72 per share, for a total transaction of $14,160.00. Following the completion of the transaction, the director owned 23,883 shares of the company’s stock, valued at approximately $112,727.76. This trade represents a 14.37% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Precision BioSciences Price Performance

NASDAQ:DTIL traded up $0.11 during midday trading on Wednesday, hitting $4.93. The company had a trading volume of 16,762 shares, compared to its average volume of 270,651. The stock’s fifty day moving average price is $5.94 and its 200-day moving average price is $5.22. The company has a market capitalization of $65.37 million, a PE ratio of -0.59 and a beta of 1.11. Precision BioSciences, Inc. has a 52-week low of $3.61 and a 52-week high of $8.82. The company has a quick ratio of 3.45, a current ratio of 3.45 and a debt-to-equity ratio of 1.35.

Precision BioSciences (NASDAQ:DTIL) last released its quarterly earnings results on Monday, November 3rd. The company reported ($1.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($1.53). Precision BioSciences had a negative net margin of 11,977.36% and a negative return on equity of 233.77%. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $5.40 million. During the same period in the previous year, the company earned ($2.25) EPS. As a group, research analysts expect that Precision BioSciences, Inc. will post -1.23 earnings per share for the current year.

Institutional Trading of Precision BioSciences

Institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC raised its stake in Precision BioSciences by 5.5% in the 2nd quarter. Geode Capital Management LLC now owns 77,712 shares of the company’s stock worth $326,000 after acquiring an additional 4,025 shares during the last quarter. Lynx1 Capital Management LP increased its holdings in shares of Precision BioSciences by 0.6% in the third quarter. Lynx1 Capital Management LP now owns 1,042,596 shares of the company’s stock valued at $5,755,000 after purchasing an additional 6,545 shares during the period. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Precision BioSciences in the third quarter valued at about $72,000. Virtu Financial LLC purchased a new position in shares of Precision BioSciences in the third quarter worth about $84,000. Finally, GSA Capital Partners LLP purchased a new position in shares of Precision BioSciences in the third quarter worth about $98,000. Institutional investors own 37.99% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Precision BioSciences in a research note on Monday. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Precision BioSciences presently has an average rating of “Hold” and a consensus target price of $47.00.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.